NCT02603328View on ClinicalTrials.gov

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

July 31, 2024

Study Completion Date

March 31, 2025

Conditions
Cerebral Cavernous Malformation
Interventions
DRUG

Atorvastatin

40-80 mg OD

OTHER

Placebo

inactive

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

University of Chicago

OTHER

NCT02603328 - Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial | Biotech Hunter | Biotech Hunter